Company Overview
Snapshot
Founded in September 2018 by Prof. Bernard Attali, Bsense Bio Therapeutics operates with 1–10 employees. The company has secured funding across one round from five investors, including Johnson & Johnson Innovation and OrbiMed.
Business overview
Bsense Bio Therapeutics is a Health Tech & Life Sciences company focused on developing small molecules for the treatment of neuropathic pain. The company's core technology involves pioneering a novel approach that targets multiple pain-related mechanisms using a single compound, specifically focusing on two cation channels (TRPV1 and Kv7.2/3) co-localized on sensory nociceptive neurons. Bsense Bio Therapeutics is currently assessing the specificity and selectivity of its lead compounds in vitro, with plans to advance into in vivo safety and efficacy studies, serving the pharmaceuticals and biotechnology sectors globally.
Log in to access full profile ›Company Intelligence Q&A
- Who founded Bsense Bio Therapeutics?
- Bsense Bio Therapeutics was founded by Prof. Bernard Attali in September 2018.
- What is Bsense Bio Therapeutics' primary focus?
- Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain, pioneering a novel approach that targets multiple pain-related mechanisms using a single compound.
- Which investors participated in Bsense Bio Therapeutics' funding round?
- In September 2018, Bsense Bio Therapeutics received seed funding from investors including Johnson &.
- What is the company's current product development stage?
- Bsense Bio Therapeutics is currently assessing the specificity and selectivity of three lead compounds in vitro, with the goal of progressing into in vivo safety and efficacy studies. The company is also performing structural activity relation studies to improve compound characteristics.
- What is the scientific basis of Bsense Bio Therapeutics' approach?
- Bsense Bio Therapeutics' approach targets two cation channels, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are recognized as significant players in pain signaling.